Assessment of Tardive Dyskinesia Using the Abnormal Involuntary Movement Scale

Lane, Richard D.; Glazer, William M.; Hansen, Tony; Berman, William; Kramer, Stephen I.

doi:10.1097/00005053-198506000-00005

Cited by 157 publications

(99 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All the subjects were assessed separately in a session lasting 2-3 h between 1100 and 1400 h. Various tests used included: i) Hindi Mental State Examination (HMSE) to assess orientation, arithmetic, memory and language (11); ii) Brief Psychiatric Rating Scale (BPRS) for psychopathology (12); iii) Trail Making Test (TMT-A/B) assessing visual attention, psychomotor speed and task switching (13); iv) Abnormal Involuntary Movement Scale (AIMS) to measure abnormal movements (14); v) The PGI-Memory scale (PGIMS) for memory (15); vi) Bender Gestalt Test (BGT) for visuo-spatial gestalt functioning and micrographia (16); vii) Finger Tapping test (FTT) for psychomotor deficits (17); viii) Verbal Adult Intelligence Scale (VAIS) to assess verbal quotient (VQ) (15); ix) Benton Visual Retention Test (BVRT) for visual perception, visual memory and visual constructive abilities (18); and x) Stroop test for executive function and response inhibition (19). Quality of physical and mental health was assessed by Short Form (SF-36) questionnaire (20).…”

Section: Neuropsychological Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium

Aggarwal

Kailash

Sagar

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: There is limited information on neuropsychological and neurological dysfunctions in patients with idiopathic hypoparathyroidism (IH). Objective: To assess neuropsychological and neurological dysfunctions in IH and its associated factors in a cross-sectional design. Method: Neuropsychological functions were assessed in 62 patients with IH and 70 controls using a battery of cognitive tests. Neurological assessment included extrapyramidal and cerebellar signs. Assessment of intracranial calcification and volume of basal ganglia calcification (BGC) were made on computed tomography and of calcium control by averaging serum total calcium values available during the follow-up. Results: A significantly higher proportion of patients with IH showed neuropsychological dysfunctions than controls (32.3 (95% CI: 20.9-45.3) vs 5.7% (95% CI: 1.6-14.0), P!0.001). Neurological signs were present in 35.5% patients (extrapyramidal: 16.1%; cerebellar: 20.9%). Volume of BGC and number of sites with intracranial calcifications including cerebellum/dentate were comparable in patients with and without neuropsychological, extrapyramidal or cerebellar dysfunctions. Cognitive dysfunction score was lower by 1.7 points in males than in females (PZ0.02) and increased by 0.21 and 5.5 for each year increase in the duration of illness (PZ0.001) and one unit increase in serum calcium-phosphorus product (PZ0.01) respectively. The scores improved by 0.27 for every mg% increase in serum calcium (PZ0.001). Conclusion: Neuropsychological dysfunctions are present in up to one-third of patients with IH and correlate with duration of illness, female gender, serum calcium and calcium-phosphorus product during follow-up but not with intracranial calcification. These dysfunctions may affect their daily functions, safety and drug compliance.

show abstract

Section: Neuropsychological Assessmentmentioning

confidence: 99%

“…The frequency of impaired cognitive dysfunction was analysed using standard cutoffs for HMSE, AIMS and VAIS (11,14,15). BPRS, TMT, BGT and BVRT tests were categorised as impaired when the raw scores of the respective tests were more than upper quartile of the values observed in the healthy controls.…”

Section: Definitions Of Impaired Cognitive Functionsmentioning

confidence: 99%

Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium

Aggarwal

Kailash

Sagar

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Response was defined as the Clinical Global Impression-Improvement (CGI-I) score of ≤ 2. Safety was also assessed weekly using The Abnormal Involuntary Movement Scale (AIMS) [16], the Barnes Akathisia Rating Scale (BARS) [17], and the Systematic Assessment for Treatment Emergent Events (SAFTEE) Adverse Symptoms Checklist.…”

Section: Discussionmentioning

confidence: 99%

Ziprasidone in Pediatric Bipolar Disorder: A 6-Week, Open-Label Comparison of Rapid vs. Slow Dose Titration

Saxena

Walley²,

Simmons³

et al. 2013

J Depress Anxiety

View full text Add to dashboard Cite

Barnett [6] in a case series (n=4;7-16 years), and Biederman et al. [7] in an eight-week, open-label trial with 21 children and adolescents (6-17 years) studied the effects of ziprasidone monotherapy in improving bipolar symptomatology in youths with bipolar disorder. In both studies, treatment with ziprasidone showed clinical improvement in the children/adolescents' bipolar symptomatology, with no significant increase in body weight.To determine the appropriate dose and titration schedule for ziprasidone in children and adolescents with bipolar disorder type 1, schizophrenia, or schizoaffective disorder, Delbello et al. [8] conducted AbstractObjective: This open-label clinical trial evaluated the dosing, safety, and effectiveness of rapid vs. slow titration of ziprasidone in pediatric bipolar disorder over a period of 6 weeks. Methods:Study participants (aged 10-17 years) were diagnosed with bipolar disorder using standardized diagnostic instruments. Additionally, standardized rating scales were used to assess changes in mood, adverse effects, and overall functioning. Twenty-eight participants were randomly assigned to either the rapid-or slow-dose titration of ziprasidone. Linear mixed model analyses of repeated measures-adjusting for the age and respective baseline clinical scorewere used to evaluate the main effects and the 2-way interaction effect (incorporating titration group and time). Cox Proportional Hazards Regression, adjusting for age, compared the time-to-treatment response for the rapid-vs. the slow-dose titration of ziprasidone. Treatment response was defined as ≥ 50% reduction from baseline on the Young Mania Rating Scale total scores for at least two sustained periods. Results:Irrespective of titration group assignment, mean YMRS total scores decreased significantly across the 6 weeks of treatment for the combined groups (p=.008). The median time to response was 2 weeks for the rapid titration group and 3 weeks for the slow group, but the two survival curves of treatment response did not differ significantly between the two titration groups (p=0.92). Overall, ziprasidone was tolerated well by the study participants in both groups (slow and rapid titration). Conclusions:No significant difference emerged between the rapid-and slow-titration groups over the 6 weeks of ziprasidone treatment on severity of manic symptoms or time-to-response. There was a reduction in manic symptoms in both the rapid and slow titration groups over the 6 week period. A much larger sample is required to test for meaningful differences between the two titration groups, in regards to improving clinical symptoms and minimizing adverse effects from ziprasidone.

show abstract

“…We assessed symptoms, health status, and medication side effects at baseline and at every three months thereafter. Symptoms were assessed with the Brief Psychiatric Rating Scale (BPRS) (13); health status by measuring body mass index (BMI), cholesterol, and glucose; and medication side effects by the Abnormal Involuntary Movement Scale (14), the Barnes Akathisia Scale (15), the Subjective Extrapyramidal Rating Scale (16), and the Modified SimpsonAngus Scale (17).…”

Section: Methodsmentioning

confidence: 99%

An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia

Glynn

Marder

Noordsy

et al. 2017

View full text Add to dashboard Cite

Objective: Although supported employment increases job acquisition for people with serious mental illness, data on participants' job tenure have been variable. This study evaluated the effects of a standardized work skills training program (the Workplace Fundamentals Module [WPFM]) on job tenure and other work outcomes among individuals receiving individual placement and support (IPS). The effects of two atypical antipsychotic medications on side effects were also tested. The primary hypothesis tested was that participants in IPS plus WPFM would have increased job tenure compared with those enrolled in IPS only, and the secondary hypothesis was that different antipsychotic medications would yield unique side effects.Methods: A 232 randomized controlled trial compared work outcomes, including job tenure, of participants receiving IPS with or without WPFM for up to two years after obtaining a job. Participants were also randomly assigned to olanzapine or risperidone. Measures of work outcomes, clinical status, and medication side effects were collected.Results: Among 107 participants, 63% obtained at least one job. WPFM did not increase job tenure (51.53 and 41.37 total weeks worked for IPS only and IPS plus WPFM, respectively) or affect other work outcomes. Participants on olanzapine experienced increased body mass index, whereas those on risperidone lost weight, but medications did not differentially affect clinical or job outcomes.Conclusions: Clinic-based skills training did not improve work outcomes accruing from IPS. Risperidone, compared with olanzapine, may reduce body mass but has no differential effect on other work or clinical outcomes.

show abstract

Assessment of Tardive Dyskinesia Using the Abnormal Involuntary Movement Scale

Cited by 157 publications

References 0 publications

Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium

Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium

Ziprasidone in Pediatric Bipolar Disorder: A 6-Week, Open-Label Comparison of Rapid vs. Slow Dose Titration

An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia

Contact Info

Product

Resources

About